Construction of a Spin-Component Scaled Dual-Hybrid Random Phase Approximation.

J Chem Theory Comput

MTA-BME Lendület Quantum Chemistry Research Group, Department of Physical Chemistry and Materials Science, Budapest University of Technology and Economics, H-1521 Budapest, Hungary.

Published: February 2017

Recently, we have constructed a dual-hybrid direct random phase approximation method, called dRPA75, and demonstrated its good performance on reaction energies, barrier heights, and noncovalent interactions of main-group elements. However, this method has also shown significant but quite systematic errors in the computed atomization energies. In this paper, we suggest a constrained spin-component scaling formalism for the dRPA75 method (SCS-dRPA75) in order to overcome the large error in the computed atomization energies, preserving the good performance of this method on spin-unpolarized systems at the same time. The SCS-dRPA75 method with the aug-cc-pVTZ basis set results in an average error lower than 1.5 kcal mol for the entire n-homodesmotic hierarchy of hydrocarbon reactions (RC0-RC5 test sets). The overall performance of this method is better than the related direct random phase approximation-based double-hybrid PWRB95 method on open-shell systems of main-group elements (from the GMTKN30 database) and comparable to the best O(N)-scaling opposite-spin second-order perturbation theory-based double-hybrid methods like PWPB95-D3 and to the O(N)-scaling RPAX2@PBEx method, which also includes exchange interactions. Furthermore, it gives well-balanced performance on many types of barrier heights similarly to the best O(N)-scaling second-order perturbation theory-based or spin-component scaled second-order perturbation theory-based double-hybrid methods such as XYG3 or DSD-PBEhB95. Finally, we show that the SCS-dRPA75 method has reduced self-interaction and delocalization errors compared to the parent dRPA75 method and a slightly smaller static correlation error than the related PWRB95 method.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jctc.6b01140DOI Listing

Publication Analysis

Top Keywords

random phase
12
second-order perturbation
12
perturbation theory-based
12
method
11
spin-component scaled
8
phase approximation
8
direct random
8
good performance
8
barrier heights
8
main-group elements
8

Similar Publications

Insomnia and some insomnia treatments can impact an individual's daytime functioning. Here, we performed post hoc analyses of patient-reported outcomes from a phase 3 clinical trial to assess the impact of lemborexant (LEM), a dual orexin receptor antagonist, on daytime functioning. Adults with insomnia were randomized 1:1:1 to receive placebo, LEM 5 mg (LEM5) or LEM 10 mg (LEM10) for 6 months.

View Article and Find Full Text PDF

Aims: This post hoc analysis aimed to assess the efficacy and safety of the non-steroidal mineralocorticoid receptor antagonist finerenone by baseline diuretic use in FIDELITY, a pre-specified pooled analysis of the phase III trials FIDELIO-DKD and FIGARO-DKD.

Methods And Results: Eligible patients with type 2 diabetes (T2D) and chronic kidney disease (CKD; urine albumin-to-creatinine ratio [UACR] ≥30-<300 mg/g and estimated glomerular filtration rate [eGFR] ≥25-≤90 ml/min/1.73 m, or UACR ≥300-≤5000 mg/g and eGFR ≥25 ml/min/1.

View Article and Find Full Text PDF

Background Cough in common cold is often associated with rhinorrhoea and nasal congestion, requiring treatment with a cough suppressant, decongestant, and antihistamine. Bilastine is a non-sedating antihistamine, a preferred option over sedating antihistamines. A combination of bilastine, dextromethorphan, and phenylephrine is expected to provide non-sedating treatment for cough associated with a common cold or allergy.

View Article and Find Full Text PDF

This study aimed to assess the efficacy and safety of a combination therapy of Allisartan Isoproxil 240 mg and Amlodipine 5 mg (ALI/AML) compared to AML 5 mg monotherapy in patients with mild-to-moderate essential hypertension. In this phase III, multicenter, double-blind, parallel-group, randomized controlled trial, patients aged 18-70 years with mean sitting systolic blood pressure (msSBP) between 140 and <180 mmHg and mean sitting diastolic blood pressure (msDBP) between 90 and <110 mmHg, following a 4-week treatment with AML 5 mg, were randomized 1:1 to receive either ALI/AML or AML once daily for 12 weeks. This 12-week double-blind period was followed by an open-label extension of ALI/AML treatment through week 52.

View Article and Find Full Text PDF

Aim: To explore the effects of sex and baseline body mass index (BMI) on the efficacy and safety of survodutide in people with a BMI ≥27 kg/m.

Materials And Methods: Totally 387 people (aged 18-75 years, BMI ≥27 kg/m, without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!